With the Science of Enzymes
In the Treatment of
Gastrointestinal and Rare Diseases
Fulfill Their Potential
Alcresta Therapeutics’ proprietary platform technology supports a broad pipeline of products, with an initial focus on pancreatic insufficiency.
The company’s technology can address unmet needs faced by people living with gastrointestinal disorders and rare diseases.
Introducing the first-of-its-kind digestive enzyme cartridge designed to mimic normal pancreatic function to break down fats in enteral tube formula.
Alcresta Therapeutics’ enzyme expertise and proprietary platform enables novel products for those with compromised pancreatic output and malabsorption.
RELiZORB significantly increased plasma levels of omega-3 fatty acids and patients reported a decrease in the frequency of gastrointestinal symptoms in a Pivotal Clinical Trial
RELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children SufferingFrom Fat Malabsorption
RELiZORB significantly increased plasma levels of DHA and EPA fatty acids and patients report a decrease in the frequency and severity of gastrointestinal symptoms